Femasys Inc Ordinary Shares FEMY 深 沪
等待开盘 09-16 09:30:00 美东时间
0.3667
-0.025
-6.48%
华盛通- 最 高0.40
- 今 开0.40
- 成交量 131.25万股
- 最 低 0.361
- 昨 收 0.3921
- 总市值 1613.63万
- 52周最高 1.80
- 市盈率 静 --
- 换手率 2.98%
- 52周最低 0.3067
- 委 比 99.57%
- 总股本 4400.40万
- 历史最高 13.75
- 量 比 0.26
- 振 幅 9.95%
- 历史最低 0.2479
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Femasys Launches FemSperm Insemination Prep Kit To Boost Gynecologist Adoption Of FemaSeed Fertility Treatment
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introduction of its FemSperm
09-11 21:05
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
Femasys Inc.推出FemSperm Insemination Prep Kit，支持妇科医生执行FemaSeed Intratubal Insemination。该产品优化精子处理，方便诊所内治疗，提高生育服务可及性。FemaSeed已获多国授权，低精子情况下的怀孕率高于传统IUI，成本低、风险低，助力公司增长。
09-11 13:00
Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
Femasys Inc. secures $8 million in financing to accelerate commercialization of its women's health products, including FemSeed® and FemBloc®, which address unmet needs in infertility and non-surgical contraception. Recent milestones include regulatory approvals for FemBloc in Europe and the UK, commercial entry into Spain, and partnerships with leading healthcare institutions. CEO Jorey Chernett highlights the importance of these innovations, emp...
09-02 13:00
生物技术公司Femasys重挫35.7%，此前宣布将公开发行募集800万美元资金
美股周二早盘，生物技术公司Femasys（FEMY）股价重挫35.7%，此前该公司宣布通过公开发行募集800万美元资金，所筹资金将用于支持该公司的商业扩张和...
08-26 23:09
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Invivyd (NASDAQ:IVVD) stock increased by 132.3% to $1.3 during Tuesday...
08-26 20:09
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
Femasys Inc. has launched the FemSperm Setup Kit, the first product in its FemSperm family, designed to enable gynecologists to offer FemaSeed Intratubal Insemination as a first-step fertility treatment. The kit simplifies sperm preparation in-office, expanding patient access to alternatives before IVF and supporting the company's commercialization strategy. FemaSeed, with proven higher pregnancy rates compared to IUI, is authorized in multiple r...
08-21 13:00
Femasys Secures UK MHRA Approval For FemBloc Non-Surgical Birth Control, Advancing European Expansion Strategy
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced that it received the Medicines and
08-20 21:02
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
Femasys Inc. has received MHRA approval for FemBloc permanent birth control in the UK, marking a key milestone in its European expansion. FemBloc, a non-surgical, first-of-its-kind solution for permanent birth control, offers a safer, more accessible, and cost-effective alternative to traditional sterilization. The approval validates the product's safety and effectiveness, enabling Femasys to serve a broader patient population in Europe. The comp...
08-20 13:00
Femasys GAAP EPS of -$0.16
Femasys press release (NASDAQ:FEMY): Q2 GAAP EPS of -$0.16. Sales increased by $187,784, or 84.8%, to $409,268 for the three months of 2025, compared to $221,484 for the three months of 2024 due to sa...
08-11 17:21
